Home » Topics » Disease categories and therapies » Substance use and poisoning

Substance use and poisoning
RSS

Japanese researchers disclose PDE7 inhibitors

March 15, 2018

University of Bristol presents new alpha4beta2 nicotinic receptor partial agonists

March 8, 2018

Anti-heroin vaccine demonstrates efficacy in rodents

March 7, 2018

Sublocade becomes available as first and only monthly injectable buprenorphine in the U.S.

March 2, 2018

NOP agonist AT-312 can reduce alcohol reward

Feb. 26, 2018

Pain Therapeutics resubmits Remoxy ER NDA

Feb. 14, 2018

Opiant Pharmaceuticals announces plans for intranasal nalmefene

Feb. 13, 2018

V1B receptor antagonism may enhance alcohol dependency treatment

Feb. 6, 2018

Achieve Life Sciences amends technology license agreement with University of Bristol

Jan. 25, 2018

AP-202 shows promise as an agent for nicotine addiction

Jan. 23, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 14, 2025.
European VCs optimistic for med-tech exit opportunities in 2025
BioWorld MedTech
To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for February 14, 2025
European VCs bullish on med-tech investments in 2025
BioWorld MedTech
European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...
Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML
BioWorld
Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...